Antwerp, May 21, 2026 (GLOBE NEWSWIRE) -- CMB.TECH  NV (“ CMBT ”, “ CMB.TECH ” or “the  c ompany”)  (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo  Børs : CMBTO) announces that today the General Meeting of Shareholders has approved the annual accounts for the year ended 31 December 202 5 . All other resolutions proposed by CMB.TECH's Supervisory Board  were also  approved.   Re appointment of Supervisory Board members  for a period of  three  years

CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript

CMB.TECH NYSE: CMBT reported a strong first quarter of 2026, with management highlighting higher revenue, reduced leverage, lower financing costs and substantial gains from vessel sales during an earnings call titled “Firing on All Cylinders.”

CMB.TECH ANNOUNCES Q1 2026 RESULTS FIRING ON ALL CYLINDERS ANTWERP, Belgium, 19 May 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the first quarter ended 31 March 2026. HIGHLIGHTS Financial highlights: Profit for the period of USD 368.8 million in Q1 2026.

Bio-Techne Corporation (TECH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

ANTWERP, Belgium, 7 May 2026 – CMB.TECH NV  (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2026 earnings prior to market opening on Tuesday 19 May 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.

Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript

Bio-Techne slips after Q3 EPS miss and revenue decline, despite operating margin expansion and strong growth in key segments.

Techne (TECH) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.56 per share a year ago.

Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. ​academic funding weighed on demand for its drug-development ‌products.